Literature DB >> 9112036

In vitro regulation of neutrophil migration by beta 2 integrins (LFA-1 and Mac-1) in patients with otitis media.

M Kamimura1, T Himi, A Kataura.   

Abstract

Beta 2 integrins are located on the surface of neutrophils and have important roles in cell migration to an inflammatory site. We investigated the inhibitory effect of antibodies to the beta 2 integrin family for neutrophil migration into middle ear effusion (MEE) during acute otitis media in children and chronic otitis media with effusion in both children and adults. Neutrophil migration to MEE samples was assessed in vitro in a 48-well Boyden chamber. The migration index value and the activity of chemoattractants in MEE was found to be proportional to the number of infiltrated cells. Migration of activated neutrophils into MEE was significantly inhibited by blocking surface-expressed cell adhesion molecules (CAM) with anti-CD11b (Mac-1 alpha) and anti-CD18 (common beta 2 subunit) antibodies (P < 0.001) but not with anti-CD11a (LFA-1 alpha) antibody. These inhibitory effects of anti-CAM antibodies were found in all types of MEE in all age groups studied. A new therapeutic approach to inflammation has been considered recently that utilizes inhibition of neutrophil migration with a blocking antibody to CAM. Our in vitro data support a possible therapeutic effect of anti-CAM antibody, indicating that administration of anti-CD11b and CD18 antibodies may be useful for treating human otitis media.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9112036     DOI: 10.1007/bf02471280

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  17 in total

1.  Quantitative analysis of soluble cell adhesion molecules in otitis media with effusion.

Authors:  T Himi; M Kamimura; A Kataura; K Imai
Journal:  Acta Otolaryngol       Date:  1994-05       Impact factor: 1.494

2.  A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte migration.

Authors:  W Falk; R H Goodwin; E J Leonard
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

3.  Cell adhesion molecules of experimental otitis media in the rat.

Authors:  M Kamimura; T Himi; A Kataura
Journal:  Acta Otolaryngol       Date:  1996-11       Impact factor: 1.494

4.  Mac-1 (CD11b/CD18) mediates adherence-dependent hydrogen peroxide production by human and canine neutrophils.

Authors:  S B Shappell; C Toman; D C Anderson; A A Taylor; M L Entman; C W Smith
Journal:  J Immunol       Date:  1990-04-01       Impact factor: 5.422

5.  The effect of anti-intercellular adhesion molecule-1 on phorbol-ester-induced rabbit lung inflammation.

Authors:  R W Barton; R Rothlein; J Ksiazek; C Kennedy
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

6.  E-selectin (endothelial-leukocyte adhesion molecule-1) is not required for the migration of neutrophils across IL-1-stimulated endothelium in vitro.

Authors:  M B Furie; M J Burns; M C Tancinco; C D Benjamin; R R Lobb
Journal:  J Immunol       Date:  1992-04-15       Impact factor: 5.422

7.  Immunologic characteristics of cytokines in otitis media with effusion.

Authors:  T Himi; T Suzuki; H Kodama; H Takezawa; A Kataura
Journal:  Ann Otol Rhinol Laryngol Suppl       Date:  1992-10

8.  Characterization of cytokines present in middle ear effusions.

Authors:  R F Yellon; G Leonard; P T Marucha; R Craven; R J Carpenter; W B Lehmann; J A Burleson; D L Kreutzer
Journal:  Laryngoscope       Date:  1991-02       Impact factor: 3.325

9.  Chemotactic factors regulate lectin adhesion molecule 1 (LECAM-1)-dependent neutrophil adhesion to cytokine-stimulated endothelial cells in vitro.

Authors:  C W Smith; T K Kishimoto; O Abbassi; B Hughes; R Rothlein; L V McIntire; E Butcher; D C Anderson; O Abbass
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

10.  Inflammatory cells in mucoid effusion of secretory otitis media.

Authors:  P Sipilä; P Karma
Journal:  Acta Otolaryngol       Date:  1982 Nov-Dec       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.